依达拉奉右莰醇治疗急性缺血性脑卒中患者的临床效果观察
Observation on Clinical Effect of Edaravone Dexborneol in the Treatment of Patients with Acute Ischemic Stroke
端木艳丽 1吕建华 1马娜2
作者信息
- 1. 濮阳市人民医院 药学部,河南濮阳 457000
- 2. 濮阳市人民医院 神经内科,河南濮阳 457000
- 折叠
摘要
目的 探讨依达拉奉右莰醇治疗急性缺血性脑卒中(AIS)患者的临床效果.方法 将 98 例AIS患者随机分为研究组(49 例)和参照组(49 例).参照组予以常规治疗,研究组在参照组基础上采用依达拉奉右莰醇治疗,比较两组的治疗效果、神经功能、血清学指标及不良反应发生率.结果 研究组治疗总有效率为 93.88%,高于参照组的 79.59%(P＜0.05).治疗后,研究组NIHSS评分、血清CRP及NSE水平低于参照组(P＜0.05).两组不良反应发生率比较无统计学差异(P＞0.05).结论 依达拉奉右莰醇治疗AIS患者效果显著,可明显促进其神经功能恢复,改善血清CRP、NSE水平,且安全可靠,值得临床推广.
Abstract
Objective To explore the clinical effect of edaravone dexborneol in the treatment of patients with acute ischemic stroke(AIS).Methods 98 AIS patients were randomly divided into study group(49 cases)and reference group(49 cases).The reference group received routine treatment,while the study group was treated with edaravone dexborneol on the basis of the reference group.The treatment effect,neurological function,serological indicators and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the study group was 93.88%,higher than 79.59%in the reference group(P<0.05).After treatment,the NIHSS score,serum CRP and NSE levels of the study group were lower than those of the reference group(P<0.05).No statistical difference was found in the incidence of adverse reactions between the two groups(P>0.05).Conclusions Edaravone dexborneol in the treatment of AIS patients has significant effect,can significantly promote the recovery of neurological function,and improve the serum CRP and NSE levels,which is safe and reliable,and worthy of clinical promotion.
关键词
急性缺血性脑卒中/依达拉奉右莰醇/NIHSS评分/血清学指标/不良反应Key words
Acute ischemic stroke/Edaravone dexborneol/NIHSS score/Serological indicator/Adverse reaction引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据